Trial Profile
A pilot study of nintedanib for lymphangioleiomyomatosis (LAM)
Status:
Recruiting
Phase of Trial:
Phase III
Latest Information Update: 19 Aug 2016
Price :
$35
*
At a glance
- Drugs Nintedanib (Primary)
- Indications Lymphangioleiomyomatosis
- Focus Therapeutic Use
- 19 Aug 2016 New trial record